Edwards Lifesciences (NYSE:EW) Upgraded at TD Cowen

TD Cowen upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a report issued on Friday morning, Marketbeat reports. They currently have $97.00 target price on the medical research company’s stock, up from their previous target price of $90.00.

Several other research analysts have also recently issued reports on EW. Jefferies Financial Group set a $98.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 29th. Oppenheimer cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Evercore ISI reiterated an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 5th. Piper Sandler reissued an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $94.57.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE:EW opened at $85.14 on Friday. The business’s 50 day moving average is $85.06 and its 200 day moving average is $80.37. The stock has a market cap of $49.41 billion, a P/E ratio of 36.70, a price-to-earnings-growth ratio of 3.46 and a beta of 0.95. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the company posted $0.67 EPS. Edwards Lifesciences’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at $3,264,127.20. This represents a 22.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 57,824 shares of company stock valued at $4,863,323. Corporate insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently modified their holdings of the stock. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $25,000. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences in the second quarter worth $28,000. True Wealth Design LLC lifted its stake in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. NewSquare Capital LLC grew its holdings in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its holdings in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.